title: [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
abstract: The platinum complex [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II),K, was tested for its antitumor activity on hormone-sensitive tumor models under peroral administration. The resorption from the gastrointestinal tract was proved by determining the estrogenic effect of K in a dose/activity study using the immature-mouse uterine weight test. In comparison to the subcutaneous injection, a tenfold peroral dose was administered to achieve identical effects. By peroral treatment of the hormone-sensitive MXT(M3.2) mammary carcinoma of the mouse with K an almost complete inhibition of the tumor growth was obtained. This effect was superior to that of subcutaneously applied cisplatin and significantly better than that obtained by perorally administered ligand L at an equimolar dose, indicating that the antitumor effect is caused by the intact complex K and not by the liberated ligand L. The strong antitumor activity of perorally applied K was also demonstrated on the hormone-sensitive Noble Nb-R prostatic carcinoma of the rat. Histological examinations showed that the platinum complex K did not cause cisplatin-like kidney damage or irritations of gastric or intestinal mucosa when given perorally.
authors.affiliation: Institut für Pharmazie, Universität Regensburg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Spruss
authors.forename: S
authors.initials: S
authors.lastname: Schertl
authors.forename: M R
authors.initials: MR
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Gust
authors.forename: K
authors.initials: K
authors.lastname: Bauer
authors.forename: H
authors.initials: H
authors.lastname: Schönenberger
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D005260:Female; D007279:Injections, Subcutaneous; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D008954:Models, Biological; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D009944:Organoplatinum Compounds / Q000494:pharmacology* / Q000633:toxicity; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014599:Uterus / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C042922:dichloro(1,2-bis(4-hydroxyphenyl)ethylenediamine)platinum II